About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01012817

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Study identifier: NCT01012817
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

Metastatic solid tumor for which curative measures do not exist (Phase I); Ovarian epithelial or primary peritoneal cancer (Phase II) refractory to platinum-based therapy or relapsed less than a year after platinum-based therapy, no more than 2 prior therapeutic regimes for ovarian or primary peritoneal cancer

Type of study:

Phase I/II study

Treatment:

28-day cycles with veliparib orally on days 1-3, 8-10, and 15-17 and topotecan hydrochloride intravenously on days 2, 9, and 16

Study sites:

Arizona
Scottsdale
Mayo Clinic in Arizona
Contact: Donald W. Northfelt 507-538-7623 Northfelt.Donald@mayo.edu

Minnesota
Rochester
Mayo Clinic
Contact: Charles Erlichman 507-538-7623 erlichman.charles@mayo.edu

Page updated 06/13/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org